Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
To the Editor: Dr Langman and colleagues1 presented data suggesting that the risk of adverse
gastrointestinal events is lower in patients taking rofecoxib than in patients
taking nonselective NSAIDs for osteoarthritis. A past history of peptic ulcer
disease was present in 10.1% of their patient population, or approximately
549 patients. It would be of considerable interest to know if the experiment
had sufficient power to detect whether the RR with rofecoxib was the same
in patients with and without a past history of peptic ulcer. An estimate of
this interaction, if it exists, would allow a more precise calculation of
the number of previously diagnosed ulcer patients needed to treat to prevent
1 recurrence of disease.
Whitney E. Rofecoxib and the Risk of Adverse Upper Gastrointestinal Effects. JAMA. 2000;283(15):1960–1961. doi:10.1001/jama.283.15.1957
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: